Valuation: Celldex Therapeutics, Inc.

Market Cap 277.47Cr 242.48Cr 223.75Cr 206.25Cr 388.73Cr 27TCr 397.36Cr 2.67TCr 1.05TCr 13TCr 1.04TCr 1.02TCr 45TCr P/E 2026 *
-8.15x
P/E 2027 * -8.09x
Enterprise Value 219.06Cr 191.43Cr 176.65Cr 162.83Cr 306.9Cr 21TCr 313.71Cr 2.11TCr 830.47Cr 10TCr 822.67Cr 804.62Cr 36TCr EV / Sales 2026 *
831x
EV / Sales 2027 * 190x
Free-Float
99.73%
Yield 2026 *
-
Yield 2027 * -
1 day-0.14%
1 week-9.61%
Current month-5.00%
1 month+9.00%
3 months+2.32%
6 months+37.82%
Current year+30.15%
1 week 34.37
Extreme 34.37
39.22
1 month 32.26
Extreme 32.26
40.3
Current year 22.33
Extreme 22.33
40.3
1 year 19.72
Extreme 19.7225
40.3
3 years 14.4
Extreme 14.4
53.18
5 years 14.4
Extreme 14.4
57.2
10 years 1.5
Extreme 1.5
75.3
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 67 30/07/2014
Chief Executive Officer 64 01/09/2008
Director of Finance/CFO 55 01/04/2009
Director TitleAgeSince
Director/Board Member 64 01/12/2008
Chairman 80 05/06/2025
Director/Board Member 93 01/03/2008
Date Insider Type Main position Quantity % Market Cap.
25/06/26 Free

Executive/Senior Manager

90,000 0.1147%
25/06/26 Free

General Counsel

95,000 0.1210%
25/06/26 Free

Director

26,000 0.0331%
Change 5-day change 1-year change 3-year change Capi.($)
-0.14%-9.61%+57.74%-2.96% 277.47Cr
-1.29%-3.11%-0.35%+3.09% 4.92TCr
+3.90%-0.39%+386.06%+593.85% 3.96TCr
-1.70%+4.46%+5.93%+60.25% 3.47TCr
-2.01%-0.76%+28.41%-8.01% 3.44TCr
+0.06%+0.34%+2.38%+34.38% 2.71TCr
+0.46%-3.49% - - 1.62TCr
-0.04%-0.09%+72.42%+115.55% 1.54TCr
+1.12%+1.91%+14.54%+19.16% 1.41TCr
0.00%+1.36%+18.43%-30.79% 1.3TCr
Average +0.04%-0.94%+65.06%+87.17% 2.46TCr
Weighted average by Cap. -0.05%-0.29%+79.18%+121.79%

Financials

2026 *2027 *
Net sales 26.35L 23.02L 21.25L 19.58L 36.91L 25Cr 37.73L 2.54Cr 99.89L 12Cr 98.95L 96.78L 43Cr 1.2Cr 1.05Cr 96.47L 88.92L 1.68Cr 115.2Cr 1.71Cr 12Cr 4.54Cr 56Cr 4.49Cr 4.39Cr 194.23Cr
Net income -33Cr -29Cr -27Cr -25Cr -46Cr -3.18TCr -47Cr -318.13Cr -125.13Cr -1.56TCr -123.95Cr -121.23Cr -5.36TCr -37Cr -32Cr -30Cr -28Cr -52Cr -3.57TCr -53Cr -357.1Cr -140.46Cr -1.75TCr -139.14Cr -136.08Cr -6.02TCr
Net Debt -58Cr -51Cr -47Cr -43Cr -82Cr -5.63TCr -84Cr -563.01Cr -221.44Cr -2.75TCr -219.36Cr -214.55Cr -9.48TCr -51Cr -44Cr -41Cr -38Cr -71Cr -4.89TCr -73Cr -489.06Cr -192.36Cr -2.39TCr -190.55Cr -186.37Cr -8.24TCr
Logo Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Employees
198
Date Price Change Volume
17/26/17 $35.35 -0.14% 11,49,060
16/26/16 $35.40 -7.60% 9,54,885
15/26/15 $38.31 +0.37% 5,34,208
14/26/14 $38.17 -0.93% 7,02,069
13/26/13 $38.53 -1.48% 6,60,189
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
35.35USD
Average target price
57.53USD
Spread / Average Target
+62.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLDX Stock